Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Kura Oncology

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2014-01-01

Employees: 142

Market Cap: $1.5B

Website: http://www.kuraoncology.com

Introduction: Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Clinical Trials

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Advanced Malignant Neoplasm
Acute Myeloid Leukemia
Mixed Lineage Leukemia
Mixed Lineage Acute Leukemia
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Acute Lymphoblastic Leukemia

Interventions: Drug: Ziftomenib
Drug: Midazolam
Drug: Itraconazole

First Posted Date: 2019-08-26

Last Posted Date: 2025-06-27

Lead Sponsor: Kura Oncology, Inc.

Target Recruit Count: 263

Registration Number: NCT04067336

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
University of Southern California, Los Angeles, California, United States

and more 50 locations

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

Phase 2

Completed

Conditions: HNSCC
HRAS Gene Mutation

Interventions: Drug: Tipifarnib
Device: HRAS Detection Assay

First Posted Date: 2018-10-25

Last Posted Date: 2024-06-21

Lead Sponsor: Kura Oncology, Inc.

Target Recruit Count: 296

Registration Number: NCT03719690

Locations: 🇺🇸
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCLA - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCSF - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

and more 98 locations

First-in-Human Study of KO-947 in Non-Hematological Malignancies

Phase 1

Terminated

Conditions: Advanced Malignant Neoplasm

Interventions: Drug: KO-947

First Posted Date: 2017-02-13

Last Posted Date: 2021-09-20

Lead Sponsor: Kura Oncology, Inc.

Target Recruit Count: 61

Registration Number: NCT03051035

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 2 locations

Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia, Myelomonocytic, Chronic

Interventions: Drug: Tipifarnib

First Posted Date: 2016-06-21

Last Posted Date: 2024-07-17

Lead Sponsor: Kura Oncology, Inc.

Target Recruit Count: 44

Registration Number: NCT02807272

Locations: 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, Florida, United States

and more 5 locations

Tipifarnib in Subjects With Myelodysplastic Syndromes

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Tipifarnib

First Posted Date: 2016-05-20

Last Posted Date: 2024-07-31

Lead Sponsor: Kura Oncology, Inc.

Target Recruit Count: 16

Registration Number: NCT02779777

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy

Phase 2

Completed

Conditions: Relapsed or Refractory Peripheral T-Cell Lymphoma

Interventions: Drug: Tipifarnib

First Posted Date: 2015-06-08

Last Posted Date: 2024-06-26

Lead Sponsor: Kura Oncology, Inc.

Target Recruit Count: 65

Registration Number: NCT02464228

Locations: 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸
Yale University, Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, Florida, United States

and more 10 locations

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Phase 2

Completed

Conditions: Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
HRAS Mutant Tumor
Thyroid Cancer
Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor

Interventions: Drug: Tipifarnib

First Posted Date: 2015-03-10

Last Posted Date: 2024-07-11

Lead Sponsor: Kura Oncology, Inc.

Target Recruit Count: 63

Registration Number: NCT02383927

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Wihship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 32 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy